Literature DB >> 19004799

BCR-ABL-transformed GMP as myeloid leukemic stem cells.

Yosuke Minami1, Scott A Stuart, Tomokatsu Ikawa, Yong Jiang, Asoka Banno, Irina C Hunton, Dennis J Young, Tomoki Naoe, Cornelis Murre, Catriona H M Jamieson, Jean Y J Wang.   

Abstract

During blast crisis of chronic myelogenous leukemia (CML), abnormal granulocyte macrophage progenitors (GMP) with nuclear beta-catenin acquire self-renewal potential and may function as leukemic stem cells (Jamieson et al. N Engl J Med, 2004). To develop a mouse model for CML-initiating GMP, we expressed p210(BCR-ABL) in an established line of E2A-knockout mouse BM cells that retain pluripotency in ex vivo culture. Expression of BCR-ABL in these cells reproducibly stimulated myeloid expansion in culture and generated leukemia-initiating cells specifically in the GMP compartment. The leukemogenic GMP displayed higher levels of beta-catenin activity than either the nontransformed GMP or the transformed nonGMP, both in culture and in transplanted mouse BM. Although E2A-deficiency may have contributed to the formation of leukemogenic GMP, restoration of E2A-function did not reverse BCR-ABL-induced transformation. These results provide further evidence that BCR-ABL-transformed GMP with abnormal beta-catenin activity can function as leukemic stem cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004799      PMCID: PMC2582213          DOI: 10.1073/pnas.0808303105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Authors:  Addolorata Maria Luce Coluccia; Angelo Vacca; Mireia Duñach; Luca Mologni; Sara Redaelli; Victor H Bustos; Daniela Benati; Lorenzo A Pinna; Carlo Gambacorti-Passerini
Journal:  EMBO J       Date:  2007-02-22       Impact factor: 11.598

Review 2.  Optimizing therapy of chronic myeloid leukemia.

Authors:  Michael W N Deininger
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

3.  Bcr is a negative regulator of the Wnt signalling pathway.

Authors:  Angelika Ress; Karin Moelling
Journal:  EMBO Rep       Date:  2005-10-07       Impact factor: 8.807

4.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Authors:  Catriona H M Jamieson; Jason Gotlib; Jeffrey A Durocher; Mark P Chao; M Rajan Mariappan; Marla Lay; Carol Jones; James L Zehnder; Stan L Lilleberg; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

6.  Tumor promotion by caspase-resistant retinoblastoma protein.

Authors:  Helena L Borges; Jeff Bird; Katherine Wasson; Robert D Cardiff; Nissi Varki; Lars Eckmann; Jean Y J Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-14       Impact factor: 11.205

7.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Authors:  Yiguo Hu; Sarah Swerdlow; Theodore M Duffy; Roberto Weinmann; Francis Y Lee; Shaoguang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

8.  Gene expression changes associated with progression and response in chronic myeloid leukemia.

Authors:  Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

Review 9.  Targeted CML therapy: controlling drug resistance, seeking cure.

Authors:  Thomas O'Hare; Amie S Corbin; Brian J Druker
Journal:  Curr Opin Genet Dev       Date:  2005-12-15       Impact factor: 5.578

10.  E proteins and Notch signaling cooperate to promote T cell lineage specification and commitment.

Authors:  Tomokatsu Ikawa; Hiroshi Kawamoto; Ananda W Goldrath; Cornelis Murre
Journal:  J Exp Med       Date:  2006-05-08       Impact factor: 14.307

View more
  44 in total

Review 1.  Molecular pathways to CML stem cells.

Authors:  Kristen N Rice; Catriona H M Jamieson
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

Review 2.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors.

Authors:  Francesca Ficara; Laura Crisafulli; Chenwei Lin; Masayuki Iwasaki; Kevin S Smith; Luca Zammataro; Michael L Cleary
Journal:  J Cell Sci       Date:  2013-05-09       Impact factor: 5.285

Review 4.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

5.  Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Authors:  Li Yin; Rehan Ahmad; Michio Kosugi; Takeshi Kawano; David Avigan; Richard Stone; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

Review 6.  Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Authors:  Y Chen; C Peng; C Sullivan; D Li; S Li
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

7.  The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.

Authors:  W Huang; C-H Luan; E E Hjort; L Bei; R Mishra; K M Sakamoto; L C Platanias; E A Eklund
Journal:  Leukemia       Date:  2016-03-17       Impact factor: 11.528

8.  Axin pathway activity regulates in vivo pY654-β-catenin accumulation and pulmonary fibrosis.

Authors:  Arnau Ulsamer; Ying Wei; Kevin K Kim; Kevin Tan; Sarah Wheeler; Ying Xi; R Scott Thies; Harold A Chapman
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

9.  Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Authors:  Okay Saydam; Yiping Shen; Thomas Würdinger; Ozlem Senol; Elvan Boke; Marianne F James; Bakhos A Tannous; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Cornel Fraefel; James F Gusella; Anna M Krichevsky; Xandra O Breakefield
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

10.  Targeting a chronic problem: elimination of cancer stem cells in CML.

Authors:  Claus Nerlov
Journal:  EMBO J       Date:  2009-02-04       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.